IMDX - Oncocyte Corp
3.56
-0.550 -15.449%
Share volume: 341,804
Last Updated: 03-27-2026
Pharmaceutical Products/In Vitro, In Vivo Diagnostic Substances:
-0.05%
PREVIOUS CLOSE
CHG
CHG%
$4.11
-0.55
-0.13%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 06-30-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 05-15-2024 | 08-08-2024 | 11-12-2024 | 03-24-2025 | 05-12-2025 | 08-11-2025 | 11-10-2025 | 03-26-2026 | |
| Total revenue | 176.000 K | 104.000 K | 115.000 K | 1.486 M | 2.138 M | 518.000 K | 260.000 K | 1.139 M | |
| Cost of revenue | 274.000 K | 54.000 K | 65.000 K | 770.000 K | 813.000 K | 168.000 K | 121.000 K | 655.000 K | |
| Gross profit | -98.000 K | 50.000 K | 50.000 K | 738.000 K | 1.325 M | 350.000 K | 139.000 K | 484.000 K | |
| 151.02% | 0.00% | 1,376.00% | 79.54% | -73.58% | -60.29% | 248.20% | |||
| Operating expenses | 5.688 M | 4.860 M | 5.382 M | 4.959 M | 6.039 M | 5.928 M | 6.423 M | 8.143 M | |
| Selling general and admin | 3.519 M | 2.407 M | 2.565 M | 2.559 M | 3.115 M | 2.647 M | 2.545 M | 2.326 M | |
| Research and development | 2.169 M | 2.453 M | 2.817 M | 2.400 M | 2.924 M | 3.281 M | 3.878 M | 5.817 M | |
| Total expenses | 5.962 M | 4.682 M | 13.565 M | 34.365 M | 8.124 M | 10.192 M | 11.187 M | 23.919 M | |
| -21.47% | 189.73% | 153.34% | -76.36% | 25.46% | 9.76% | 113.81% | |||
| Operating income | -5.786 M | -4.632 M | -13.515 M | -33.627 M | -6.799 M | -9.842 M | -11.048 M | -23.435 M | |
| Ebit | -5.786 M | -4.522 M | -13.462 M | -33.481 M | -6.642 M | -9.717 M | -10.825 M | -22.929 M | |
| Pretax income | -9.129 M | -4.530 M | -13.493 M | -33.511 M | -6.671 M | -9.742 M | -10.854 M | -22.955 M | |
| -50.38% | 197.86% | 148.36% | -80.09% | 46.04% | 11.41% | 111.49% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | -9.129 M | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| 100.00% | |||||||||
| Net income | -9.129 M | -4.530 M | -13.493 M | -33.511 M | -6.671 M | -9.742 M | -10.854 M | -22.955 M | |
| 50.38% | -197.86% | -148.36% | 80.09% | -46.04% | -11.41% | -111.49% |